BSECompany Update1 Nov 2026 · 1 Nov 2026, 07:08 pm
Investor Presentation
Shree Ganesh Remedies Ltd · 540737
✦ AI SummaryResults
Shree Ganesh Remedies Ltd has released an investor presentation for Q2 and H1FY27, highlighting a challenging start to the year due to subdued input costs and demand, but showing improvement in Q2 with a focus on core CRAMS business and new product development.
Analysis Scores
Earnings Impact4/10
Growth Catalyst6/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Shree Ganesh Remedies Ltd - 540737 - Announcement under Regulation 30 (LODR)-Investor Presentation
Attachments (1)
📄pdf
Download →
37a0fb05-2914-414b-b796-9ae9322aace9.pdf
View document text
November 01, 2026
The BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001
Scrip Code: 540737
Dear Sir/Ma’am,
Sub: Investor Presentation
With reference to the captioned subject, we enclose herewith the Investor Presentation with
respect to Unaudited Financial Results of the Company for the quarter and half year ended
September 30, 2026.
Kindly take the same on your record.
Thanking You,
Yours faithfully
For Shree Ganesh Remedies Limited
Akanksha
Company Secretary and Compliance Officer
Enc. a/a
Investor Presentation
Q2 & H1FY27
Innovate.
React.
Transform.
Inside the
19 Dahej Land Acquisition Setting the Stage for Large Scale Projects
Forward
20 Driving Innovation Through Strategic R&D Investments
Presentation
Looking
21 State-of-the-Art R&D Infrastructure
Statement
22 State-of-the-Art Pilot Infrastructure
In so far as forecasts or
23 Accreditations that Speak to Our Comprehensive Standards
expectations are
24 Driving Innovation and Growth expressed in this
Quarterly Highlights
presentation or where
25 Ensuring Health and Safety
our statements concern
04 Management Commentary
26 Protecting the Environment With Sustainable Practices the future, these
05 P&L Summary forecasts, expectations
or statements may
06 Balance Sheet Summary
involve known or
07 Cash Flow Summary unknown risks and
uncertainties. Actual
results or developments
Financial Highlights may vary, depending on
changes in the
28 5 Year Summary operating environment.
About the Business
Shree Ganesh Remedies
29 Key Ratios
09 Excellence in Complex Chemistry Limited does not
30 P&L Summary assume an obligation to
10 Unparalleled Expertise in Advanced Chemical Synthesis
update the forecasts,
31 Balance Sheet Summary
12 Unmatched Technology Prowess In Complex Chemical Reactions expectations or
32 Cash Flow Summary statements contained in
13 Tailored Solutions Through Mastered Chemistry and Technology
this presentation.
14 Strategic Product Selection Criteria
15 Our Evolving Business Model
16 Collaborating With Industry Leaders
Investment Merits
17 Ankleshwar Site Expansion Fuelling Our Growth Strategy
34 Investment Case
18 Infrastructure at Ankleshwar Site
Shree Ganesh Remedies Limited
Quarterly Highlights
Management Commentary 04
P&L Summary 05
Balance Sheet Summary 06
Cash Flow Summary 07
QUARTERLY HIGHLIGHTS
Management Commentary
FY27 began on a challenging note for the Company. Subdued expect input costs to ease as geopolitical conditions stabilise,
demand from Europe and a difficult operating environment and margins to normalise as our sales return to earlier levels.
weighed on our first-quarter performance. Over the past Throughout, we remain focused on healthy profitability,
three months, we have worked steadily through these including on the new products we are developing.
challenges, and this is reflected in an improved performance
in Q2FY27. As we work towards this recovery, we continue to build the
businesses that will drive our next phase of growth. Our
Much of this improvement has come from our core CRAMS business has made strong progress during the
pharmaceutical intermediates business, where we sharpened quarter. On our specialty chemicals project for South-East
our focus on the domestic market to make up for softer Asian markets, we have successfully completed the pilot trials,
exports. Alongside this, we have begun to see improved and the batches are now undergoing stability testing, with
traction from our European customers, which gives us commercial supplies expected from Q1FY28. A second
confidence that the core business will recover to its earlier specialty chemicals product for the same region has cleared
levels over the next few quarters. We have also broadened laboratory trials and moved to the pilot stage. In Europe, we
our portfolio during the quarter by commencing commercial are making positive progress on two molecules for
production of two new pharmaceutical intermediates, one for pharmaceutical and agrochemical applications. To support
anti-diabetic and one for cardiovascular applications. Both this pipeline, construction of Block 7A is now complete and
have received an encouraging response in the domestic trials have begun.
market, and we plan to take them to export markets in the
coming quarters. This year has brought its own set of challenges, and we have
responded by strengthening our domestic presence, adding
While volumes are on the path to recovery, they remain to our product portfolio and advancing our CRAMS pipeline.
below earlier levels, and this has put some pressure on our With the core business recovering, new products gaining
margins. Raw material prices added to this pressure, rising traction and new capacity coming online, we look forward to
significantly and staying volatile through the quarter. We a stronger performance in the periods ahead.
Gunjan Kothia
Promoter, Head of Business Development & Innovation
Shree Ganesh Remedies Limited
QUARTERLY HIGHLIGHTS
P&L Summary
-23% -59% -67%
YoY Change
Revenue EBITDA PAT
YoY QoQ YoY
PARTICULARS Q2FY26 Q1FY27 Q2FY27 H1FY26 H1FY27
(₹ IN CRORES)
Change Change Change
Revenue from Operations 30.32 14.36 23.29 -23% 62% 54.98 37.65 -32%
Total Income 31.00 15.30 24.70 -20% 61% 56.33 40.00 -29%
Operating Expenses 20.70 11.01 19.36 -6% 76% 38.07 30.37 -20%
EBITDA (Excluding OI & EI) 9.62 3.35 3.94 -59% 17% 16.92 7.29 -57%
EBITDA % 31.7% 23.3% 16.9% -1,483 bps -644 bps 30.8% 19.4% -1141bps
Finance Cost 1.01 0.32 0.58 -43% 80% 1.95 0.89 -54%
Depreciation & Ammortization 2.59 2.44 2.50 -3% 3% 5.01 4.94 -1%
PBT 6.71 1.53 2.26 -66% 48% 11.31 3.79 -66%
PAT 4.96 1.12 1.63 -67% 46% 8.41 2.75 -67%
EPS (₹) 3.86 0.87 1.28 -67% 47% 6.55 2.15 -67%
Shree Ganesh Remedies Limited
QUARTERLY HIGHLIGHTS
Balance Sheet Summary
PARTICULARS FY26 H1FY27
(₹ IN CRORES)
Shareholders' Funds 163.02 165.79
Non-Current Liabilities 23.03 22.61
Long Term Borrowings 21.25 20.62
Current Liabilities 21.69 21.97
Short Term Borrowings 9.42 5.37
Trade Payables 9.44 14.84
Total Equity and Liabilities 207.74 210.37
Non-Current Assets 121.91 122.85
Tangible Assets 68.08 64.63
CWIP 12.38 16.30
Current Assets 85.83 87.52
Inventories 24.01 33.53
Trade Receivables 32.57 21.12
Cash & Bank Balances 13.45 17.36
Investments 12.45 11.38
Total Assets 207.74 210.37
Shree Ganesh Remedies Limited
QUARTERLY HIGHLIGHTS
Cash Flow Summary
PARTICULARS H1FY26 H1FY27
(₹ IN CRORES)
Cash from Operating Activities 17.66 14.64
Cash from Investing Activities -8.23 -5.17
Cash from Financing Activities -5.73 -5.55
Net Cash Flow 3.70 3.92
Cash at the Beginning of Year 11.12 13.36
Cash at the End of Year 14.82 17.28
Shree Ganesh Remedies Limited
About the Business
Excellence in Complex Chemistry 09
Unparalleled Expertise in Advanced Chemical Synthesis 10
Unmatched Technology Prowess In Complex Chemical Reactions 12
Tailored Solutions Through Mastered Chemistry and Technology 13
Strategic Product Selection Criteria 14
Our Evolving Business Model 15
Collaborating With Industry Leaders 16
Ankleshwar Site Expansion Fuelling Our Growth Strategy 17
Infrastructure at Ankleshwar Site 18
Dahej Land Acquisition Setting the Stage for Large Scale Projects 19
Driving Innovation Through Strategic R&D Investments 20
State-of-the-Art R&D Infrastructure 21
State-of-the-Art Pilot Infrastructure 22
Accreditations that Speak to Our Comprehensive Standards 23
Driving Innovation and Growth 24
Ensuring Health and Safety 25
Protecting the Environment With Sustainable Practices 26
ABOUT THE COMPANY
Excellence in Complex Chemistry
Established Expertise Strategic Expansions
Over 21 years of excellence in chemical Continuous investments in new manufacturing
manufacturing, specialising in pharmaceutical blocks and R&D centers to enhance production
intermediates and speciality chemicals. capacity and innovation.
Global Reach Trusted Partner
Serving over 21 countries, including key Trusted partner for leading global companies,
markets in the EU and the US, with a offering reliable and high
[Showing first 8,000 characters — download PDF for full document]